نتایج جستجو برای: zolpidem tartrate

تعداد نتایج: 3908  

2014
Camille Chatelle Aurore Thibaut Olivia Gosseries Marie-Aurélie Bruno Athena Demertzi Claire Bernard Roland Hustinx Luaba Tshibanda Mohamed A. Bahri Steven Laureys

BACKGROUND Zolpidem, a short-acting non-benzodiazepine GABA agonist hypnotic, has been shown to induce paradoxical responses in some patients with disorders of consciousness (DOC), leading to recovery of arousal and cognitive abilities. We here assessed zolpidem-induced changes in regional brain metabolism in three patients with known zolpidem response in chronic post-anoxic minimally conscious...

Journal: :Debates em Psiquiatria 2023

Introdução: Rabdomiólise é uma condição em que ocorre a destruição e necrose muscular. De etiologia variada, pode estar associada crises convulsivas. O zolpidem um agente sedativo hipnótico não benzodiazepínico sob condições de abuso frequência ocasionar Relato Caso: Homem, 26 anos, foi levado à emergência hospital geral por ansiedade, onde apresentou episódios Quadro evolui para rabdomiólise. ...

Journal: :Journal of analytical toxicology 2014
Kristi S Thompson Russell J Lewis Roxane M Ritter

Zolpidem is a nonbenzodiazepine sedative hypnotic drug used for the short-term treatment of insomnia. While quite effective in producing sedation, zolpidem has potentially hazardous side effects when put in the context of complex tasks. Therefore, to more fully understand the postmortem concentrations of zolpidem, our laboratory has developed a sensitive method for the quantitation of zolpidem ...

Journal: :Clinical pharmacology and therapeutics 1998
D J Greenblatt J S Harmatz L L von Moltke B L Ehrenberg L Harrel K Corbett M Counihan J A Graf M Darwish P Mertzanis P T Martin W H Cevallos R I Shader

PURPOSE This study evaluated the relationship of dose, plasma concentration, and time to the pharmacodynamics of zaleplon and zolpidem, 2 structurally distinct benzodiazepine receptor agonists. METHOD Ten healthy male volunteers received single oral doses of placebo, 10 mg zaleplon, 20 mg zaleplon, 10 mg zolpidem, and 20 mg zolpidem in a double-blind, 5-condition crossover study, with 48 hour...

Journal: :The Journal of pharmacology and experimental therapeutics 1997
J K Rowlett W L Woolverton

The present study compared the discriminative stimulus effects of the imidazopyridine, zolpidem, with a triazolobenzodiazepine, triazolam, in pentobarbital-trained rhesus monkeys and rats. Rhesus monkeys (n = 4), trained to discriminate pentobarbital (10 mg/kg intragastric [i.g.]) from saline under a FR 1 discrete-trials shock avoidance procedure, were given zolpidem (0.10-30 mg/kg i.g.) or tri...

Journal: :BioMedicine 2016
Shih-Wei Lai

Zolpidem is a non-benzodiazepine hypnotic drug commonly used for the treatment of insomnia. However, to date, extensive evidence has shown that zolpidem use is a factor associated with certain clinical conditions, not that it treats these conditions. The aim of this review is to summarize current published articles on the risks and benefits of zolpidem use.

2017
Alicia Nevriana Jette Möller Lucie Laflamme Joel Monárrez-Espino

BACKGROUND Previous studies on the effect of zolpidem or zopiclone use on the risk of road traffic crashes (RTCs) have shown mixed results. OBJECTIVE Our objective was to determine the association between zolpidem or zopiclone use (as separate drugs or combined) and the occurrence of injurious RTCs among older adult drivers. METHODS This was a population-based matched case-control and case-...

2008
LG Olson

Zolpidem, zopiclone and zaleplon are hypnotics with similar pharmacology to benzodiazepines. In addition to the usual adverse effects of sedative drugs, there have been unusual reactions associated with the 'z-drugs', particularly zolpidem. It is unclear why there have been so many reports of bizarre behaviour in Australians taking zolpidem. Some of the cases may be the result of other conditio...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 1998
S Allard S Sainati B Roth-Schechter J MacIntyre

The objective was to evaluate possible pharmacokinetic and pharmacodynamic interactions for repeated nightly zolpidem dosing with fluoxetine. Twenty-nine healthy female volunteers (mean age, 25. 6 years) received zolpidem (10 mg) and fluoxetine (20 mg) in the following open design: zolpidem on night 1 followed by 1 washout day, a daily morning dose of fluoxetine on days 3 through 27, and a morn...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید